Company

In July 2020, the U.S. Food and Drug Administration granted accelerated approval of Monjuvi® (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. We are very proud that we could bring a new treatment option to thousands of patients and are a commercial-stage biopharma company now.

In 2017, Tremfya® (guselkumab) became the first drug based on MorphoSys' antibody technology to receive regulatory approval. Today, the blockbuster drug is approved for both plaque psoriasis and psoriatic arthritis in the US and Europe, and several other countries. Janssen Research & Development, LLC is running a broad clinical development program for guselkumab in various indications, including Crohn's disease and Ulcerative colitis. Tremfya® is marketed by Janssen Biotech, Inc.

Being able to help patients, give them hope and provide them with the best treatment available is the strongest motivation driving our more than 750 employees across Germany and the United States. As of July 15, 2021, Constellation Pharmaceuticals is a MorphoSys company. Together, we come to work every day, driven to make a difference.

Management

Open and complete information is a guiding principle for the cooperation of MorphoSys’ Management Board and Supervisory Board. They work closely together and make decisions for the benefit of the company. Their commitment objective is the sustainable increase in the company’s value.

Executive Committee

Dr. Jean-Paul Kress

Chief Executive Officer

Biography

Dr. Jean-Paul Kress

Chief Executive Officer

Year of Birth	1965
Nationality	French
Management Board Member of MorphoSys AG since	2019
End of current appointment	2022

Dr. Jean-Paul Kress joined MorphoSys as CEO in September 2019. As a trained physician, Jean-Paul has devoted his career to bringing transformative therapies to patients. Since joining MorphoSys, he has strategically repositioned the company from a leading antibody technology provider to a biopharma company with a robust late-stage pipeline.

Prior to joining MorphoSys, Jean-Paul served as President and Chief Executive Officer at Syntimmune, a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases, which was acquired by Alexion in November 2018. Among other assignments, he was Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen, and Senior Vice President, Head of North America at Sanofi Genzyme, where he was instrumental in launching Dupilumab, the first biologic agent approved in atopic dermatitis. Previously, he was President and Chief Executive Officer of Sanofi Pasteur MSD, and gained additional experience in positions at Gilead, Abbvie and Eli Lilly.

Jean-Paul Kress received an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in biochemistry and in molecular and cellular pharmacology from Ecole Normale Supérieure in Paris.

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

Erytech Pharma SA, Lyon, France (publicly listed Company)

Chairman of the Board of Directors

As of January 2021

Sung Lee

Chief Financial Officer

Biography

Sung Lee

Chief Financial Officer

Year of Birth	1970
Nationality	American
Management Board Member of MorphoSys AG since	2021
End of current appointment	2024

Sung Lee came to MorphoSys in February 2021 and leads all corporate finance functions of the company.

Sung Lee has more than 20 years of finance leadership experience in biopharmaceutical and technology businesses. He joined MorphoSys from Sangamo Therapeutics, Inc., where he served as Chief Financial Officer. Prior to that role, Mr. Lee spent nearly 14 years at Gilead Sciences where he most recently led the global Financial Planning & Analysis and Investor Relations functions.

Lee started his career in the tax advisory business at PriceWaterhouseCoopers LLP. He received a Master of Business Taxation from the University of Southern California and a B.A. in Economics from the University of California, Irvine.

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

None

As of January 2021

Charlotte Lohmann

SVP General Counsel

Biography

Charlotte Lohmann

SVP General Counsel

Charlotte Lohmann joined MorphoSys in May 2012. She is a very experienced lawyer with more than 20 years of professional practice, having worked in both top tier international audit and law firms as well as in publicly listed biotech companies.
She is an accomplished executive that has established solution-oriented legal departments with a focus on performance, effectiveness and making the legal department a true business partner. She has been successful in setting up and executing international projects as well as public listings on Frankfurt Stock Exchange and Nasdaq and has vast experience in advising management and supervisory boards (both as General Counsel and supervisory board member).
Prior to joining MorphoSys she worked for Wilex AG as Sr. VP Legal Affairs & Human Resources and for KPMG as Corporate Lawyer.
Charlotte Lohmann holds a Law Degree from the University of Munich and is an accredited lawyer in Germany.

Dr. Malte Peters

Chief Research and Development Officer

Biography

Dr. Malte Peters

Chief Research and Development Officer

Year of Birth	1962
Nationality	German
Management Board Member of MorphoSys AG since	2017
End of current appointment	2022

Dr. Peters joined MorphoSys from Sandoz International, Holzkirchen, Germany, where he was Global Head of Clinical Development of the Biopharmaceuticals Business Unit. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.

Dr. Peters received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany. After scientific work at different universities he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Tango Therapeutics, Cambridge, MA, U.S. (not publicly listed company; group mandate)

Member of the Board of Directors

As of January 2021

Dr. Barbara Krebs-Pohl

SVP, Global Head of BD&L and Alliance Management

Biography

Dr. Barbara Krebs-Pohl

SVP, Global Head of BD&L and Alliance Management

Dr. Barbara Krebs-Pohl is a highly regarded business development executive with an outstanding track record of accomplishment of revenues and forging successful alliances with pharma and biotechnology companies worldwide.

Since joining MorphoSys in 1998, Dr. Krebs-Pohl has successfully led R&D teams, international alliances and negotiation teams spanning a broad variety of deal structures. She has been instrumental in program search & evaluation, portfolio strategy and a multitude of transactions, including the in-licensing of tafasitamab from Xencor, the long-term HuCAL alliance with Novartis and the co-development and co-commercialization partnership with Incyte. She is also the winner of the "Astra Zeneca Business Development Executive of the Year 2013" Award.

Prior to joining MorphoSys, Dr. Krebs-Pohl earned the opportunity to work with Nobel Prize winner Sir Greg Winter at MRC/LMB Cambridge, UK. She holds a PhD from the University of Mainz in Immunology, theoretical Physics and Biochemistry. She is a Master of Science (MSc) Chemistry from the University of Cologne and further trained at the RWTH Aachen University with focus on Medical Biology and Bacteriology.

Maria Castresana

SVP Global Head of Human Resources

Biography

Maria Castresana

SVP Global Head of Human Resources

Maria Castresana is a global HR Executive with extensive international experience in the pharmaceutical and chemical industry gained over more than 20 years of professional experience in Spain, Germany and the USA.

Prior to joining MorphoSys in 2020, Maria Castresana held positions of increasing responsibility at Boehringer Ingelheim, a global pharmaceutical player that expanded in recent years into oncology and specialty. She lately served as Global Head of Talent, Leadership & Organizational Effectiveness. Among other assignments, she was Global Business Partner for Consumer Health Care and led the carve-out and sale of the business in the frame of BI's and Sanofi's SWAP of CHC and Animal Health business, which closed on January 1st, 2017. Furthermore, she spent several years in the USA and was instrumental in the set-up of new commercial launch teams for Oncology, Diabetes and Cardiovascular.

Previously, she also worked for Ecolab as European Compensation Manager and gained early experience at Bayer.

Maria Castresana received a Law Degree and a Business Administration Degree from the University of Deusto in Spain and a Master in Human Resources from Rutgers University in the USA.

Daniel Palmacci

SVP Global Head of Technical Operations

Biography

Daniel Palmacci

SVP Global Head of Technical Operations

Daniel Palmacci brings over 20 years of experience in the international pharmaceutical industry with responsibility for Manufacturing, Supply Chain and Operational Excellence, leading cross-functional teams responsible for Pharmaceutical cGMP Production of Biologics API and sterile Fill & Finish, Manufacturing Science & Technology and Launch Management of new biotech products and biosimilars.

Before joining MorphoSys he has been working in various senior roles at MSD and Novartis in Germany, Austria and Switzerland. He spent many years in the United States, where he was responsible for the construction of the new cGMP certified biopharmaceutical facility at Schering AG, Seattle. Later Daniel took over the responsibility for a biopharmaceutical manufacturing facility for BayerHealthCare in the United States. He has a wide multicultural experience through international assignments in Germany, Italy, India, Brazil and the US.

Daniel holds a master’s degree in Chemistry and Process Engineering from the University of Berlin.

Supervisory Board

The Supervisory Board oversees and advises the Management Board. The Board consists of professionally qualified members with many years of experience in the biotechnology and pharmaceutical industries.

Dr. Marc Cluzel

Chairman

Biography and additional memberships

Dr. Marc Cluzel

Chairman

Year of birth	1955
Nationality	French
Place of residence	Montpellier, France
Initial appointment	2012
End of current period	2024

Professional Development

Currently	Member of the Supervisory Board of MorphoSys AG as well as member of comparable foreign supervisory board of a commercial enterprise (see below)
2011 – 2012	Executive Vice President of Product Development, HÙYÀ Bioscience International, LLC, San Diego, CA, USA
2009 - 2010	Executive Vice President of Research & Development, Sanofi-Aventis S.A., Paris, France
2007 – 2009	Senior Vice President of Science and Medical Affairs, Sanofi-Aventis S.A., Paris, France
2002 – 2011	Chairman and CEO, Sanofi-Aventis R&D France, Paris, France
1996 – 2001	Head of Project Direction, Sanofi R&D France, Paris, France
1993 – 1996	Project Director, Sanofi R&D France, Paris, France
1991 – 1993	Clinical Pharmacologist, Sanofi R&D France, Montpellier, France

Education

1983 – 1990	Ph.D. Biochemistry at University of Montpellier, France
1973 – 1985	M.D., Study of Medicine at University of Montpellier, France

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Moleac Pte. Ltd., Singapore*	Member of the Board of Directors
Griffon Pharmaceuticals Inc., Montreal, Canada*	Member of the Board of Directors

*not publicly listed company; group mandate

As of February 2021

Dr. George Golumbeski

Deputy Chairman

Biography and additional memberships

Dr. George Golumbeski

Deputy Chairman

Year of birth	1957
Nationality	US-American
Place of residence	Far Hills, NJ, USA
Initial appointment	2018
End of current period	2023

Professional Development

Since 2018	Business consultant in the life sciences and healthcare industries
2018 - 2019	President, Grail Inc., Menlo Park, CA, USA
2017 – 2018	Executive Vice President & Executive Advisor for Innovation, Celgene Corporation, Summit, NJ, USA
2009 – 2017	Executive Vice President, Business Development, Celgene Corporation, Summit, NJ, USA
2008 – 2009	Chief Executive Officer, Nabriva Therapeutics AG, Vienna, Austria
2002 – 2008	Vice President, Business Development, Licensing & Strategy, Novartis Oncology, Florham Park, NJ, USA
2001 – 2002	Vice President, R&D Business Development, Elan Biopharmaceuticals, San Diego, CA, USA
2000 – 2001	Senior Director, Licensing, EMD Pharmaceuticals, Durham, NC, USA
1997 – 2000	Vice President / Director, Corporate Development, Schwarz Pharma, Mequon, WI, USA
1996 – 1997	Director, Business Development, Pierce Chemical Company, Rockford, IL, USA
1991 – 1995	Technology Acquisition Manager / Group Leader, Research & Development / Group Leader, Diagnostics Research & Development, Promega Corporation, Madison, WI, USA

Education

1986 – 1991	Postdoctoral Research, Molecular biology, University of Colorado Boulder, Boulder, CO, USA
1979 – 1985	Ph.D., Genetics, University of Wisconsin-Madison, Madison, WI, USA
1975 – 1979	B.A., Biology, University of Virginia, Charlottesville, VA, USA

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Carrick Therapeutics Ltd., Dublin, Ireland*	Chairman of the Board of Directors
Ananke Therapeutics, Inc., Boston, MA, USA*	Chairman of the Board of Directors
Sage Therapeutics, Inc., Cambridge, MA, USA (publicly listed company)	Member of the Board of Directors
Shattuck Labs, Inc., Austin, TX, USA (publicly listed company)	Member of the Board of Directors

* not publicly listed company; group mandate

As of November 2021

Krisja Vermeylen

Member

Biography and additional memberships

Krisja Vermeylen

Member

Year of birth	1962
Nationality	Belgian
Place of residence	Herentals, Belgium
Initial appointment	2017
End of current period	2024

Professional Development

Currently	Business consultant in the life science and healthcare industries
2015 - 2018	Senior Vice President Corporate People & Organisation, Novo Nordisk A/S, Bagsvaerd, Denmark
2013 – 2015	Corporate Vice President and General Manager (CVP), Novo Nordisk Pharma GmbH, Mainz, Germany
2008 – 2013	Vice President (France & BeLux), Novo Nordisk SA, Paris, France
2002 – 2013	Vice President Europe West (France, Belgium, Luxembourg, Netherlands), Novo Nordisk SA, Paris, France
1998 – 2002	General Manager (BeLux & Director GHT France), Novo Nordisk SA, Brussels, Belgium
1997 – 1998	Marketing & Sales Manager Diabetes/Women Health Care/Growth Hormone/Haemophilia, Novo Nordisk SA, Brussels, Belgium
1997	Marketing Manager Diabetes/Women Health Care/Growth Hormone, Novo Nordisk SA, Brussels, Belgium
1996 – 1997	Senior Product Manager Anaesthesia and Cardiovascular, Pharmacia & Upjohn, Brussels, Belgium
1995	Product & Sales Manager Low molecular weight heparin, Pharmacia, Brussels, Belgium
1994 – 1995	Product Manager Anaesthesia and Cardiovascular, Pharmacia, Brussels, Belgium
1993 – 1994	Product Manager Anaesthesia, Pharmacia, Brussels, Belgium
1991 – 1993	Medical Representative Hospital Division Parenteral Nutrition, Kabi Pharmacia, Brussels, Belgium
1986 – 1991	Pharmacist dispenser

Education

2015 - 2017	Independent Director Program (IDP) INSEAD France
2002	Advanced Management Program (AMP) INSEAD France
1985 – 1986	Doctoral student of bromatology at the University of Antwerp (UIA), Antwerp, Belgium
1980 – 1985	Pharmacist / Master in pharmaceutical sciences at the University of Antwerp (UIA, RUCA), Antwerp, Belgium

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Diaverum AB, Lund, Sweden*

Member of the Board of Directors

*not publicly listed company; group mandate

As of February 2021

Michael Brosnan

Member

Biography and additional memberships

Michael Brosnan

Member

Year of birth	1955
Nationality	US-American
Place of residence	Westford, MA, USA
Initial appointment	2018
End of current period	2023

Professional development

Currently	Freelance business consultant in the life sciences and healthcare industries
2010 - 2019	Chief Financial Officer, Fresenius Medical Care Management AG, Bad Homburg v.d.H, Germany
2003 – 2009	Executive Vice President and Chief Financial Officer, Fresenius Medical Care North America, Waltham, MA, USA
1999 – 2003	Senior Vice President of Finance, Fresenius Medical Care North America, Waltham, MA, USA
1998	Vice President Finance and Administration, Spectra Renal Management, Waltham, MA, USA
1997	Vice President of Financial Operations, High Voltage Engineering Corporation, Wakefield, MA, USA
1994 – 1996	Senior Controller, Commercial Imaging Group, Polaroid Corporation, Cambridge, MA, USA
1978 – 1993	KPMG, Boston, MA, USA, (1988 – 1993 Audit Partner)

Education

1978	BSc, Business Administration, Accounting, Northeastern University, Boston, MA, USA

NO MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

As of February 2021

Sharon Curran

Member

Biography and additional memberships

Sharon Curran

Member

Year of birth	1968
Nationality	Irish
Place of residence	Dublin, Ireland
Initial appointment	2019
End of current period	2024

PROFESSIONAL DEVELOPMENT

Currently	Non-Executive Director in life sciences and healthcare industries
2014 – 2017	Vice President, Global Specialty Franchise & Customer Excellence, AbbVie, Chicago, IL, USA
2012 – 2014	Vice President and Senior Director, Global Marketing Specialty, Global Marketing & Commercial Operations, AbbVie, Chicago, IL, USA
2009 – 2012	Global Brand & Commercial Director, Abbott International Office, Ireland
2002 – 2008	Divisional Head, Strategy & Operations, Eli Lilly, UK & Ireland
1999 – 2002	Divisional Head, Primary Care Strategy & Operations, Eli Lilly, UK
1996 – 1999	Group Marketing/Business Unit Manager, Eli Lilly, Dublin, Ireland
1995 - 1996	Hospital Sales Specialist, Eli Lilly, Dublin, Ireland
1993 – 1995	Hospital Sales Representative, Novo Nordisk, Dublin, Ireland
1992 – 1993	Medical Device Sales Representative, Dublin, Ireland

EDUCATION

2007 - 2008	MSc Business Administration, Trinity College Dublin, Ireland
1989 -1992	BSc Biotechnology, Dublin City University, Ireland
1986 – 1989	Associate of Institute of Medical Laboratory Science, DIT/ Technological University, Dublin, Ireland

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

CAT Capital Topco Limited, Saint Peter Port, Guernsey*

Member of the Board of Directors

CAT Capital Bidco Limited, Dublin, Ireland*

Member of the Board of Directors

Circassia Pharmaceuticals plc., Oxford,

United Kingdom (publicly listed company)

Member of the Board of Directors

*not publicly listed company; group mandate

As of February 2021

Wendy Johnson

Member

Biography and additional memberships

Wendy Johnson

Member

Year of birth	1952
Nationality	US-American
Place of residence	San Diego, CA, USA
Initial appointment	2015
End of current period	2022

Professional Development

Currently	Chief Development Officer, Reneo Pharmaceuticals, San Diego, CA, USA; Managing Director, Gemini Advisors, San Diego, CA, USA
2007 – 2014	Founder, President and CEO, Aires Pharmaceuticals, Inc., San Diego, CA, USA
2005 – 2014	Venture Partner, ProQuest Investments, San Diego, CA, USA
2001 – 2005	Senior Vice President Corporate Development, Salmedix, Inc., San Diego, CA, USA
2000 – 2001	Independent Consultant, San Diego, CA, USA
2000 – 1998	Vice President Business Development, Women First HealthCare, San Diego, CA, USA
1998 – 1994	Vice President Corporate Development & Operations, Selective Genetics, San Diego, CA, USA
1994 – 1990	Vice President Business Development & Regulatory Affairs, Cytel Corp., San Diego, CA, USA
1990 – 1988	Manager Business Development, Synbiotics Corp., San Diego, CA, USA
1988 – 1986	International Business Development & Regulatory Affairs Manager, Murex Corp., Cambridge, Great Britain
1986 – 1976	Assistant Director, US Food & Drug Administration, Center for Devices & Radiological Health, Rockville, MD, USA

Education

1986 – 1984	M.B.A., Loyola Marymount University, Los Angeles, CA, USA
1976 – 1974	M.S. Clinical Microbiology, Hahnemann University Hospital, Philadelphia, PA, USA
1974 – 1970	B.S. Microbiology, University of Maryland, College Park, MD, USA

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Exagen, Inc., Vista, CA, USA

Member of the Board of Directors

* not publicly listed company; group mandate

As of February 2021

Composition of the Supervisory Board SINCE Termination of the 2021 Annual General Meeting

	Initial Appointment	End of Current Period	Audit Committee	Remuneration and Nomination Committee	Science and Technology Committee
Dr. Marc Cluzel	2012	2024		M
Krisja Vermeylen	2017	2024	M	C
Wendy Johnson	2015	2022		M	M
Dr. George Golumbeski	2018	2023			C
Michael Brosnan (FE)	2018	2023	C
Sharon Curran	2019	2024	M

FE=Independent Financial Expert C=Chairperson M=Member

MorphoSys in a nutshell

Management

Executive Committee

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Related links

The company's philosophy

Compliance and transparency

Supervisory Board

Professional Development

Education

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Professional Development

Education

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Professional Development

Education

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Professional development

Education

NO MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

PROFESSIONAL DEVELOPMENT

EDUCATION

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

Professional Development

Education

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Composition of the Supervisory Board SINCE Termination of the 2021 Annual General Meeting

MorphoSys in a nutshell

You are here

Management

Executive Committee

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Related links

The company's philosophy

Compliance and transparency

Supervisory Board

Professional Development

Education

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Professional Development

Education

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Professional Development

Education

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Professional development

Education

NO MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

PROFESSIONAL DEVELOPMENT

EDUCATION

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

Professional Development

Education

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Composition of the Supervisory Board SINCE Termination of the 2021 Annual General Meeting

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

You are leaving morphosys.com and will be transferred to the Monjuvi(®) US website which is intended for US residents.

Welcome to the MorphoSys Global website. This site is intended for non-US residents.

Welcome to the MorphoSys Global website.
This site is intended for non-US residents.